Curis Company Profile (NASDAQ:CRIS)

About Curis (NASDAQ:CRIS)

Curis, Inc. is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company's drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target programmed death ligand-1 (PDL1) and V-domain Ig suppressor of T-cell activation (VISTA) immune checkpoint proteins, both of which independently function as negative regulators of immune activation. CA-4948 is an oral small molecule drug candidate that is designed to inhibit the Interleukin-1 receptor-associated kinase 4 (IRAK4) kinase, which is a transducer of toll-like receptor or certain interleukin receptor signaling pathways.

Industry, Sector and Symbol:

Sector: Medical
Industry: Biotechnology & Medical Research - NEC
Sub-Industry: Biotechnology
Symbol: NASDAQ:CRIS
CUSIP: 23126910
Web: www.curis.com

Capitalization:

Market Cap: $294.73 million
Outstanding Shares: 143,772,000

Average Prices:

50 Day Moving Avg: $1.94
200 Day Moving Avg: $2.37
52 Week Range: $1.57 - $3.72

P/E:

Trailing P/E Ratio: N/A
Foreward P/E Ratio: -5.39
P/E Growth: 0.00

Sales & Book Value:

Annual Revenue: $7.93 million
Price / Sales: 37.17
Book Value: $0.15 per share
Price / Book: 13.67

Profitability:

EBIDTA: ($46,080,000.00)
Net Margins: -841.05%
Return on Equity: -163.29%
Return on Assets: -80.97%

Debt:

Debt-to-Equity Ratio: 1.92%
Current Ratio: 5.86%
Quick Ratio: 5.86%

Misc:

Average Volume: 556,819 shs.
Beta: 1.87
Short Ratio: 3.74

Frequently Asked Questions for Curis (NASDAQ:CRIS)

What is Curis' stock symbol?

Curis trades on the NASDAQ under the ticker symbol "CRIS."

How were Curis' earnings last quarter?

Curis, Inc. (NASDAQ:CRIS) issued its quarterly earnings data on Thursday, May, 4th. The company reported ($0.11) EPS for the quarter, missing analysts' consensus estimates of ($0.09) by $0.02. The company had revenue of $2.13 million for the quarter, compared to analyst estimates of $1.98 million. Curis had a negative return on equity of 163.29% and a negative net margin of 841.05%. The company's revenue was up 23.1% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.07) earnings per share. View Curis' Earnings History.

When will Curis make its next earnings announcement?

Curis is scheduled to release their next quarterly earnings announcement on Wednesday, August, 2nd 2017. View Earnings Estimates for Curis.

Where is Curis' stock going? Where will Curis' stock price be in 2017?

4 brokers have issued twelve-month price targets for Curis' stock. Their forecasts range from $6.00 to $7.00. On average, they expect Curis' stock price to reach $6.67 in the next twelve months. View Analyst Ratings for Curis.

What are analysts saying about Curis stock?

Here are some recent quotes from research analysts about Curis stock:

1. According to Zacks Investment Research, "Curis, Inc. is a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, with technologies that utilize regulatory pathways that control repair and regeneration. Curis' product development involves the use of small molecules or proteins to modulate these pathways. The company has successfully used this technology and product development approach to produce several promising drug product candidates in the fields of cancer, neurological disorders, hair growth, kidney and other diseases, as well as cardiovascular disease. " (7/17/2017)
2. Cowen and Company analysts commented, "In our view, recent underperformance of CRIS shares is not reflective of the continued." (5/5/2017)

Who are some of Curis' key competitors?

Some companies that are related to Curis include ANI Pharmaceuticals (ANIP), Mesoblast Limited (MESO), WAVE Life Sciences (WVE), ImmunoGen (IMGN), Agenus (AGEN), Cara Therapeutics (CARA), AC Immune SA (ACIU), Inovio Pharmaceuticals (INO), Adamas Pharmaceuticals (ADMS), PDL BioPharma (PDLI), Abeona Therapeutics (ABEO), Concert Pharmaceuticals (CNCE), Celyad SA (CYAD), Novavax (NVAX), Idera Pharmaceuticals (IDRA), Puretech Health PLC (PRTC), Celldex Therapeutics (CLDX) and Advaxis (ADXS).

Who are Curis' key executives?

Curis' management team includes the folowing people:

James R. McNab Jr., Independent Chairman of the Board
Ali Fattaey Ph.D., President, Chief Executive Officer, Director
James E. Dentzer, Chief Financial Officer, Chief Administrative Officer
Mani Mohindru Ph.D., Chief Strategy Officer
David Tuck M.D., Chief Medical Officer
Lori A. Kunkel M.D., Director
Martyn D. Greenacre, Independent Director
Kenneth I. Kaitin Ph.D., Independent Director
Robert E. Martell M.D., Ph.D., Independent Director
Kenneth J. Pienta M.D., Independent Director

How do I buy Curis stock?

Shares of Curis can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Curis' stock price today?

One share of Curis stock can currently be purchased for approximately $2.05.

MarketBeat Community Rating for Curis (NASDAQ CRIS)

Community Ranking:		3.1 out of 5 ( )
Outperform Votes:		176 (Vote Outperform)
Underperform Votes:		108 (Vote Underperform)
Total Votes:		284

MarketBeat's community ratings are surveys of what our community members think about Curis and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Consensus Ratings for Curis (NASDAQ:CRIS) (How are Consensus Ratings Calculated?)

Ratings Breakdown:	4 Buy Ratings
Consensus Rating:	Buy (Score: 3.00)
Consensus Price Target:	$6.67 (225.20% upside)

Analysts' Ratings History for Curis (NASDAQ:CRIS)

Show:

Date	Firm	Action	Rating	Price Target	Impact on Share Price
5/15/2017	Cowen and Company	Reiterated Rating	Buy		N/A
3/11/2017	FBR & Co	Set Price Target	Buy	$6.00	Low
10/12/2016	Royal Bank Of Canada	Set Price Target	Buy	$7.00	N/A
9/7/2016	Robert W. Baird	Reiterated Rating	Outperform	$7.00	N/A
3/1/2016	SunTrust Banks, Inc.	Initiated Coverage	Buy	$3.00	N/A
2/29/2016	Roth Capital	Reiterated Rating	Buy	$5.00	N/A

(Data available from 7/25/2015 forward)

Earnings History for Curis (NASDAQ:CRIS)

Earnings by Quarter for Curis (NASDAQ:CRIS)

Earnings History by Quarter for Curis (NASDAQ CRIS)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
8/2/2017
5/4/2017	Q1 17	($0.09)	($0.11)	$1.98 million	$2.13 million	View	Listen
3/9/2017	Q4 2016	($0.10)	($0.08)	$1.97 million	$2.40 million	View	Listen
11/3/2016	Q316	($0.10)	($0.21)	$1.84 million	$1.80 million	View	Listen
8/4/2016	Q216	($0.09)	($0.09)	$2.05 million	$1.70 million	View	Listen
5/9/2016	Q116	($0.08)	($0.07)	$2.30 million	$1.70 million	View	Listen
2/29/2016	Q415	($0.12)	($0.10)	$2.98 million	$2.10 million	View	Listen
11/9/2015	Q315	($0.08)	($0.04)	$2.82 million	$2.00 million	View	N/A
8/6/2015	Q215	($0.06)	($0.06)	$3.50 million	$2.10 million	View	N/A
5/7/2015	Q115	($0.06)	($0.07)	$2.27 million	$1.17 million	View	N/A
2/24/2015	Q4 14	($0.07)	($0.07)	$2.69 million	$2.00 million	View	N/A
11/10/2014	Q314	($0.05)	($0.06)	$4.13 million	$1.80 million	View	N/A
8/7/2014	Q214	($0.06)	($0.02)	$3.46 million	$4.80 million	View	N/A
5/8/2014	Q114	($0.07)	($0.06)	$1.88 million	$1.30 million	View	N/A
2/20/2014	Q413	($0.08)	($0.05)	$1.59 million	$1.52 million	View	N/A
11/5/2013	Q313	($0.01)	($0.02)	$6.44 million	$7.20 million	View	N/A
8/5/2013	Q2 2013	($0.05)	($0.02)	$4.43 million	$5.40 million	View	N/A
4/30/2013	Q1 2013	($0.05)	($0.06)	$3.86 million	$0.90 million	View	N/A
2/20/2013	Q4 2012	($0.08)	($0.15)	$2.07 million	$1.69 million	View	N/A
11/6/2012	Q312	($0.08)	($0.04)	$1.01 million	$0.60 million	View	N/A
8/2/2012		($0.05)	($0.04)			View	N/A
5/8/2012		$0.02	$0.03			View	N/A
10/27/2011		($0.07)	($0.05)			View	N/A
7/28/2011		($0.07)	($0.06)			View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for Curis (NASDAQ:CRIS)

2017 EPS Consensus Estimate: ($0.28)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2017	1	($0.08)	($0.08)	($0.08)
Q2 2017	1	($0.07)	($0.07)	($0.07)
Q3 2017	1	($0.07)	($0.07)	($0.07)
Q4 2017	1	($0.06)	($0.06)	($0.06)

(Data provided by Zacks Investment Research)

Dividend History for Curis (NASDAQ:CRIS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading and Institutional Ownership History for Curis (NASDAQ:CRIS)

Insider Ownership Percentage: 4.07%
Institutional Ownership Percentage: 51.68%

Institutional Ownership by Quarter for Curis (NASDAQ:CRIS)

Insider Trades by Quarter for Curis (NASDAQ:CRIS)

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
5/5/2017	James R Mcnab	Director	Sell	76,276	$2.04	$155,603.04
5/2/2017	James R Mcnab	Director	Sell	116,708	$2.38	$277,765.04
4/27/2017	James R Mcnab	Director	Sell	146,694	$2.61	$382,871.34
4/24/2017	James R Mcnab	Director	Sell	110,322	$2.59	$285,733.98
9/7/2016	Discovery Technologie Aurigene	Major Shareholder	Buy	10,208,333	$2.40	$24,499,999.20
5/27/2016	Martyn D Greenacre	Director	Sell	15,000	$1.69	$25,350.00
5/26/2016	Kenneth I Kaitin	Director	Sell	15,000	$1.76	$26,400.00
12/30/2015	Daniel R. Passeri	Director	Sell	14,400	$3.01	$43,344.00
12/29/2015	Daniel R. Passeri	Director	Sell	11,200	$2.91	$32,592.00
12/28/2015	Daniel R. Passeri	Director	Sell	13,600	$2.85	$38,760.00
12/23/2015	Daniel R. Passeri	Director	Sell	48,900	$2.78	$135,942.00
12/21/2015	Daniel R. Passeri	Director	Sell	289,000	$2.99	$864,110.00
8/27/2014	Ali Ph.D. Fattaey	CEO	Buy	62,890	$1.60	$100,624.00
12/11/2013	Ali Ph.D. Fattaey	COO	Buy	3,000	$2.52	$7,560.00
11/12/2013	Michael Gray	CFO	Buy	10,000	$2.86	$28,600.00
11/8/2013	Kenneth Pienta	Director	Buy	20,000	$2.95	$59,000.00
8/16/2013	James Mcnab	Director	Sell	50,000	$4.00	$200,000.00
12/6/2012	Daniel R Passeri	CEO	Buy	25,000	$3.03	$75,750.00

(Data available from 1/1/2013 forward)

Headline Trends for Curis (NASDAQ:CRIS) Latest Headlines for Curis (NASDAQ:CRIS)

Source:

Date	Headline
	Curis, Inc. (CRIS) Given Consensus Rating of "Buy" by Analysts www.americanbankingnews.com - July 18 at 1:53 PM
	Curis, Inc. (CRIS) Rating Increased to Hold at Zacks Investment Research www.americanbankingnews.com - July 17 at 8:26 PM
	Technical Insights on Biotech Stocks -- Curis, OvaScience, Regulus Therapeutics, and Vanda Pharma www.bizjournals.com - July 12 at 11:14 PM
	Technical Insights on Biotech Stocks -- Curis, OvaScience, Regulus Therapeutics, and Vanda Pharma - PR Newswire (press release) www.prnewswire.com - July 12 at 6:12 PM
	A Look At Geron's Potential Myelofibrosis Competition seekingalpha.com - July 5 at 6:12 PM
	Brokerages Anticipate Curis, Inc. (CRIS) Will Announce Quarterly Sales of $2.06 Million www.americanbankingnews.com - July 2 at 9:46 AM
	-$0.09 Earnings Per Share Expected for Curis, Inc. (CRIS) This Quarter www.americanbankingnews.com - June 30 at 9:10 AM
	ETFs with exposure to Curis, Inc. : June 26, 2017 finance.yahoo.com - June 26 at 5:18 PM
	Curis, Inc. (CRIS) Upgraded by ValuEngine to Hold www.americanbankingnews.com - June 25 at 12:10 AM
	Curis, Inc. (CRIS) Given Consensus Recommendation of "Buy" by Brokerages www.americanbankingnews.com - June 22 at 4:44 PM
	Analysts Expect Curis, Inc. (CRIS) Will Announce Quarterly Sales of $2.06 Million www.americanbankingnews.com - June 8 at 1:10 PM
	Zacks: Brokerages Expect Curis, Inc. (CRIS) Will Post Earnings of -$0.09 Per Share www.americanbankingnews.com - June 6 at 7:14 AM
	UPDATE - Curis to Present at the Jefferies Healthcare Conference - GlobeNewswire (press release) globenewswire.com - June 2 at 3:07 AM
	Curis to Present at the Jefferies Healthcare Conference finance.yahoo.com - June 1 at 5:04 PM
	UPDATE - Curis to Present at the Jefferies Healthcare Conference finance.yahoo.com - June 1 at 5:04 PM
	Curis, Inc. (CRIS) Sees Significant Increase in Short Interest www.americanbankingnews.com - May 28 at 8:14 AM
	Curis Announces Presentations Related to CA-170 and CUDC-907 at 2017 ASCO Annual Meeting finance.yahoo.com - May 25 at 6:04 PM
	ETFs with exposure to Curis, Inc. : May 22, 2017 finance.yahoo.com - May 22 at 4:19 PM
	Curis, Inc. (CRIS) Expected to Post Quarterly Sales of $2.06 Million www.americanbankingnews.com - May 12 at 1:36 PM
	ETFs with exposure to Curis, Inc. : May 11, 2017 finance.yahoo.com - May 11 at 5:06 PM
	Zacks Investment Research Downgrades Curis, Inc. (CRIS) to Sell www.americanbankingnews.com - May 10 at 8:56 PM
	Zacks: Analysts Expect Curis, Inc. (CRIS) to Post -$0.09 EPS www.americanbankingnews.com - May 10 at 4:26 PM
	Curis, Inc. :CRIS-US: Earnings Analysis: Q1, 2017 By the Numbers : May 9, 2017 finance.yahoo.com - May 9 at 4:28 PM
	Curis, Inc. 52 Weeks Later: The Risk Grows, But The Investment Thesis Remains Promising seekingalpha.com - May 5 at 9:44 PM
	Curis, Inc. (CRIS) Stock Rating Reaffirmed by Cowen and Company www.americanbankingnews.com - May 5 at 9:34 PM
	James R. Mcnab Sells 76,276 Shares of Curis, Inc. (CRIS) Stock www.americanbankingnews.com - May 5 at 8:37 PM
	Curis, Inc. (CRIS) Posts Quarterly Earnings Results, Misses Estimates By $0.02 EPS www.americanbankingnews.com - May 4 at 11:10 PM
	Edited Transcript of CRIS earnings conference call or presentation 4-May-17 12:30pm GMT finance.yahoo.com - May 4 at 9:40 PM
	EARNINGS SUMMARY: Details of Curis Inc Q1 Earnings Report www.rttnews.com - May 4 at 4:37 PM
	Curis Chairman James McNab Jr. To Retire, Martyn Greenacre Named Successor www.nasdaq.com - May 4 at 4:37 PM
	Investor Network: Curis, Inc. to Host Earnings Call finance.yahoo.com - May 4 at 4:37 PM
	Curis reports 1Q loss marketbeat.com - May 4 at 8:19 AM
	Curis Reports First Quarter 2017 Financial Results feeds.benzinga.com - May 4 at 7:31 AM
	Favorable Media Coverage Somewhat Unlikely to Affect Curis (CRIS) Share Price www.americanbankingnews.com - May 3 at 12:46 AM
	Curis, Inc. (CRIS) Director James R. Mcnab Sells 116,708 Shares www.americanbankingnews.com - May 2 at 9:54 PM
	Curis (CRIS) Receiving Positive Press Coverage, Analysis Finds www.americanbankingnews.com - April 29 at 6:11 PM
	Curis to Release First Quarter 2017 Financial Results and Hold Conference Call on May 4, 2017 finance.yahoo.com - April 28 at 5:27 PM
	James R. Mcnab Sells 146,694 Shares of Curis, Inc. (CRIS) Stock www.americanbankingnews.com - April 27 at 9:40 PM
	Curis, Inc. – Value Analysis (NASDAQ:CRIS) : April 25, 2017 finance.yahoo.com - April 27 at 2:11 AM
	Curis, Inc. (CRIS) Expected to Announce Earnings of -$0.09 Per Share www.americanbankingnews.com - April 27 at 1:14 AM
	Zacks: Brokerages Anticipate Curis, Inc. (CRIS) Will Post Quarterly Sales of $2 Million www.americanbankingnews.com - April 27 at 1:13 AM
	Curis (CRIS) Getting Positive Media Coverage, Study Finds www.americanbankingnews.com - April 27 at 12:48 AM
	Curis, Inc. breached its 50 day moving average in a Bearish Manner : CRIS-US : April 24, 2017 finance.yahoo.com - April 24 at 9:24 AM
	Curis (CRIS) Earns Daily Media Sentiment Score of 0.33 www.americanbankingnews.com - April 23 at 2:09 PM
	Curis, Inc. (CRIS) Expected to Post Quarterly Sales of $2 Million www.americanbankingnews.com - April 21 at 2:04 PM
	Somewhat Positive News Coverage Extremely Likely to Affect Curis (CRIS) Stock Price www.americanbankingnews.com - April 20 at 6:38 PM
	Curis (CRIS) Earns Media Impact Rating of 0.31 www.americanbankingnews.com - April 17 at 9:38 AM
	Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) finance.yahoo.com - April 7 at 9:12 AM
	Curis, Inc. breached its 50 day moving average in a Bearish Manner : CRIS-US : April 6, 2017 finance.yahoo.com - April 7 at 9:12 AM
	Curis (CRIS) to Unveil Pre-Clinical Data on IRAK4 Kinase Inhibitor CA-4948 at AACR Meeting 4/1-4/5 www.streetinsider.com - March 30 at 4:56 PM